Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.69−0.02 (-3.12%)
Close on Nov 13, 2026Market cap $26.13MP/E –Yield –
Metagenomi Therapeutics cash
Cash and short-term investments held at the end of each period.
Metagenomi Therapeutics's cash was $101.70M at Sep 30, 2026. For fiscal 2025 it was $160.80M, down 35.2% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.80M | -35.2% |
| FY2024 | Dec 31, 2024 | $248.30M | -10.2% |
| FY2023 | Dec 31, 2023 | $276.43M | +45.1% |
| FY2022 | Dec 31, 2022 | $190.51M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $101.70M | -44.8% |
| Q2 FY2026 | Jun 30, 2026 | $120.70M | -41.1% |
| Q1 FY2026 | Mar 31, 2026 | $140.20M | -38.0% |
| Q4 FY2025 | Dec 31, 2025 | $160.80M | -35.2% |
| Q3 FY2025 | Sep 30, 2025 | $184.10M | -33.0% |
| Q2 FY2025 | Jun 30, 2025 | $205.00M | -31.6% |
| Q1 FY2025 | Mar 31, 2025 | $226.00M | -31.0% |
| Q4 FY2024 | Dec 31, 2024 | $248.30M | -10.2% |
| Q3 FY2024 | Sep 30, 2024 | $274.60M | +169.5% |
| Q2 FY2024 | Jun 30, 2024 | $299.90M | +480.7% |
| Q1 FY2024 | Mar 31, 2024 | $327.40M | +242.2% |
| Q4 FY2023 | Dec 31, 2023 | $276.43M | +45.1% |
| Q3 FY2023 | Sep 30, 2023 | $101.90M | – |
| Q2 FY2023 | Jun 30, 2023 | $51.65M | – |
| Q1 FY2023 | Mar 31, 2023 | $95.67M | – |
| Q4 FY2022 | Dec 31, 2022 | $190.51M | – |
See a number that looks wrong?